HXB2 Stock Overview
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AIM ImmunoTech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$0.66 |
| 52 Week Low | US$0.24 |
| Beta | -0.15 |
| 1 Month Change | -12.38% |
| 3 Month Change | -3.28% |
| 1 Year Change | -8.76% |
| 3 Year Change | -78.80% |
| 5 Year Change | -92.11% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| HXB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | 1.8% | -0.3% |
| 1Y | -8.8% | -19.9% | 2.8% |
Return vs Industry: HXB2 exceeded the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: HXB2 underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| HXB2 volatility | |
|---|---|
| HXB2 Average Weekly Movement | 22.2% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HXB2's share price has been volatile over the past 3 months.
Volatility Over Time: HXB2's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 27 | Thomas Equels | aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
| HXB2 fundamental statistics | |
|---|---|
| Market cap | €19.47m |
| Earnings (TTM) | -€26.90m |
| Revenue (TTM) | €187.62k |
103.8x
P/S Ratio-0.7x
P/E RatioIs HXB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HXB2 income statement (TTM) | |
|---|---|
| Revenue | US$202.00k |
| Cost of Revenue | US$42.00k |
| Gross Profit | US$160.00k |
| Other Expenses | US$29.12m |
| Earnings | -US$28.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 79.21% |
| Net Profit Margin | -14,337.62% |
| Debt/Equity Ratio | 0% |
How did HXB2 perform over the long term?
See historical performance and comparison